Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine

By sjmartinez • November 29, 2022

Edwards GG, Miyashita-Ochoa A, Castillo EG, Goodman-Meza D, Kalofonos I, Landovitz RJ, Leibowitz AA, Pulsipher C, El Sayed E, Shoptaw S, Shover CL, Tabajonda M, Yang YS, Harawa NT. Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS Behav. 2022 Sep 5:1–15. doi: 10.1007/s10461-022-03817-z. Epub ahead of print. PMID: 36063243; PMCID: PMC9443641.

Tags: Addiction medicine, Antiretroviral medication, Cost, HIV treatment, Implementation barriers and facilitators, Infectious Diseases, Long acting injectable medication, Psychiatry, Publications

Related Posts

Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study

Phiri K, Hagstrom C, Lungu E, Balakasi K, Songo J, Makwaya A, Smith D, Worku A, Hoffman R, Phiri S, Dovel K, van Oosterhout JJ.[...]

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV

Rozek GM, Yang P, Eby Y, Benner SE, Martens C, Habtehyimer F, Chahoud M, Brown D, Desai NM, Florman S, Rana MM, Pereira MR, Hand[...]